{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:42:01Z","timestamp":1764603721175,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Malaria infection is still known to be a worldwide public health problem, especially in tropical and sub-tropical African countries like Sudan. A pilot study conducted to describe the trend of<jats:italic>P. falciparum<\/jats:italic>drug resistance markers in 2017\u20132018 in comparison to CQ and AS\/SP eras in Sudan. The<jats:italic>Pfcrt<\/jats:italic>,<jats:italic>Pfmdr-1<\/jats:italic>,<jats:italic>Pfdhfr<\/jats:italic>, and<jats:italic>Pfdhps<\/jats:italic>genes were investigated. Data deposited by the worldwide antimalarial resistance network was consulted, and the molecular markers previously reported from Sudan were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Drug molecular markers analysis was successfully done on 20<jats:italic>P. falciparum<\/jats:italic>isolates. The<jats:italic>Pfcrt<\/jats:italic>K76 showed high frequency; 16 (80%). For the<jats:italic>Pfmdr-1,<\/jats:italic>9 (45%) isolates were carrying the N86 allele, and 11 (55%) were 86Y allele. While the Y184F of the<jats:italic>Pfmdr-1<\/jats:italic>showed a higher frequency of 184F compared to Y184; 16 (80%) and 4 (20%), respectively. In the<jats:italic>Pfdhfr<\/jats:italic>, 51I allele showed higher frequency compared to N51; 18 (90%) and 2 (10%), respectively. For S108N, 18 (90%) were 108\u00a0N and 2 (10%) were S108. In the<jats:italic>Pfdhps<\/jats:italic>, all isolates were carrying the mutant alleles; 437G and 540E. The frequency distribution of the<jats:italic>Pfcrt<\/jats:italic>,<jats:italic>Pfmdr-1<\/jats:italic>,<jats:italic>Pfdhfr<\/jats:italic>,<jats:italic>Pfdhps<\/jats:italic>was significantly different across the whole years in Sudan.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13104-020-05363-0","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T13:02:38Z","timestamp":1604754158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A snapshot of Plasmodium falciparum malaria drug resistance markers in Sudan: a pilot study"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-3361","authenticated-orcid":false,"given":"Nouh S.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanadi","family":"Abdelbagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussam A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa M.","family":"Yousif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusraa B.","family":"Edris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Y.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aahd R.","family":"Elsadig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel E.","family":"Siddig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madinna","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha M.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rihab A.","family":"Omer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol H.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"key":"5363_CR1","unstructured":"WHO: World malaria report 2019. Geneva: World Health Organization 2019."},{"key":"5363_CR2","volume-title":"Assessment of the sensitivity of Plasmodium falciparum to antimalarial drugs at Sennar, Sudan: use of the in vitro micro-technique and the in vivo method","author":"R Kouznetsov","year":"1979","unstructured":"Kouznetsov R, Rooney W, Wernsdorfer W, El Gaddal A, Payne D, Abdalla R. Assessment of the sensitivity of Plasmodium falciparum to antimalarial drugs at Sennar, Sudan: use of the in vitro micro-technique and the in vivo method. Geneva: World Health Organization; 1979."},{"key":"5363_CR3","first-page":"1","volume":"1","author":"EM Malik","year":"2004","unstructured":"Malik EM, Khalafalla O. Malaria in Sudan: past, present and the future. Gezira J Health Sci. 2004;1:1\u20139.","journal-title":"Gezira J Health Sci."},{"key":"5363_CR4","unstructured":"Sudan Malaria Diagnosis and Treatment Protocol. 2017. https:\/\/reliefweb.int\/report\/sudan\/sudan-malaria-diagnosis-and-treatment-protocol-2017#:~:text=Sudan%20Malaria%20Treatment%20Protocol%2C%202017,Gedarif%20State%20(%3E10%25). Accessed 2 July 2020."},{"key":"5363_CR5","doi-asserted-by":"crossref","unstructured":"Adam I, Ibrahim M, Aelbasit I, El Bashir M. Efficacy of sulfadoxine\/pyrimethamine for uncomplicated Plasmodium falciparum malaria in a small sample of Sudanese children. pp 309\u2013314, 2004.","DOI":"10.26719\/2004.10.3.309"},{"key":"5363_CR6","first-page":"147","volume":"26","author":"MT Salah","year":"2005","unstructured":"Salah MT, Mohammed MM, Himeidan YE, Malik EM, Elbashir MI, Adam I. A randomized comparison of sulphadoxine\u2013pyrimethamine and combination of sulphadoxine pyrimethamine with chloroquine in the treatment of uncomplicated falciparum malaria in Eastern Sudan. Saudi Med J. 2005;26:147\u20138.","journal-title":"Saudi Med J"},{"key":"5363_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1475-2875-4-41","volume":"4","author":"SB Elamin","year":"2005","unstructured":"Elamin SB, Malik EM, Abdelgadir T, Khamiss AH, Mohammed MM, Ahmed ES, Adam I. Artesunate plus sulfadoxine\u2013pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Malar J. 2005;4:41.","journal-title":"Malar J"},{"key":"5363_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1179\/136485905X36299","volume":"99","author":"I Adam","year":"2005","unstructured":"Adam I, A-Elbasit I, Idris S, Malik E, Elbashir M. A comparison of the efficacy of artesunate plus sulfadoxine\u2013pyrimethamine with that of sulfadoxine\u2013pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol. 2005;99:449\u201355.","journal-title":"Ann Trop Med Parasitol"},{"key":"5363_CR9","first-page":"8","volume":"12","author":"AA Adeel","year":"2012","unstructured":"Adeel AA. Drug-resistant malaria in Sudan: a review of evidence and scenarios for the future. Sudan J Paediatr. 2012;12:8.","journal-title":"Sudan J Paediatr"},{"key":"5363_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1046\/j.1365-2958.2000.01914.x","volume":"36","author":"MT Duraisingh","year":"2000","unstructured":"Duraisingh MT, Roper C, Walliker D, Warhurst DC. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol. 2000;36:955\u201361.","journal-title":"Mol Microbiol"},{"key":"5363_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1475-2875-12-103","volume":"12","author":"M Malmberg","year":"2013","unstructured":"Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, Petzold M, Premji Z, Gil JP, Bjorkman A, Martensson A. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance\/resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103.","journal-title":"Malar J"},{"key":"5363_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438\u201347.","journal-title":"Lancet"},{"key":"5363_CR13","doi-asserted-by":"publisher","first-page":"e02309","DOI":"10.1128\/AAC.02309-17","volume":"62","author":"A Mukherjee","year":"2018","unstructured":"Mukherjee A, Gagnon D, Wirth DF, Richard D. Inactivation of plasmepsins 2 and 3 sensitizes Plasmodium falciparum to the antimalarial drug piperaquine. Antimicrob Agents Chemother. 2018;62:e02309-02317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5363_CR14","doi-asserted-by":"crossref","unstructured":"Ecker A, Lehane AM, Fidock DA. Molecular markers of Plasmodium resistance to antimalarials. In: Treatment and prevention of malaria. Basel: Springer; 2011. p 249\u2013280","DOI":"10.1007\/978-3-0346-0480-2_13"},{"key":"5363_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0003-2697(88)90047-4","volume":"174","author":"TA Ciulla","year":"1988","unstructured":"Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem. 1988;174:485\u20138.","journal-title":"Anal Biochem"},{"key":"5363_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0166-6851(93)90050-8","volume":"58","author":"G Snounou","year":"1993","unstructured":"Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol. 1993;58:283\u201392.","journal-title":"Mol Biochem Parasitol"},{"key":"5363_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12936-017-1791-2","volume":"16","author":"OA Salem","year":"2017","unstructured":"Salem OA, Mint Lekweiry K, Bouchiba H, Pascual A, Pradines B. Characterization of Plasmodium falciparum genes associated with drug resistance in Hodh Elgharbi, a malaria hotspot near Malian\u2013Mauritanian border. Malar J. 2017;16:140.","journal-title":"Malar J"},{"key":"5363_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13071-017-2298-y","volume":"10","author":"F Lu","year":"2017","unstructured":"Lu F, Zhang M, Culleton RL, Xu S, Tang J, Zhou H, Zhu G, Gu Y, Zhang C, Liu Y, et al. Return of chloroquine sensitivity to Africa? Surveillance of African Plasmodium falciparum chloroquine resistance through malaria imported to China. Parasit Vectors. 2017;10:355.","journal-title":"Parasit Vectors"},{"key":"5363_CR19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/infdis\/jiu216","volume":"210","author":"AE Frosch","year":"2014","unstructured":"Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, Dzinjalamala FK, Plowe CV. Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis. 2014;210:1110\u20134.","journal-title":"J Infect Dis"},{"key":"5363_CR20","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJMoa062032","volume":"355","author":"MK Laufer","year":"2006","unstructured":"Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959\u201366.","journal-title":"N Engl J Med"},{"key":"5363_CR21","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.4269\/ajtmh.2006.75.1182","volume":"75","author":"EA Temu","year":"2006","unstructured":"Temu EA, Kimani I, Tuno N, Kawada H, Minjas JN, Takagi M. Monitoring chloroquine resistance using Plasmodium falciparum parasites isolated from wild mosquitoes in Tanzania. Am J Trop Med Hyg. 2006;75:1182\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5363_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1637-3","volume":"15","author":"S Mwanza","year":"2016","unstructured":"Mwanza S, Joshi S, Nambozi M, Chileshe J, Malunga P, Kabuya J-BB, Hachizovu S, Manyando C, Mulenga M, Laufer M. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malar J. 2016;15:1\u20136.","journal-title":"Malar J"},{"key":"5363_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.meegid.2006.03.008","volume":"7","author":"ME Osman","year":"2007","unstructured":"Osman ME, Mockenhaupt FP, Bienzle U, Elbashir MI, Giha HA. Field-based evidence for linkage of mutations associated with chloroquine (pfcrt\/pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr\/pfdhps) resistance and for the fitness cost of multiple mutations in P. falciparum. Infect Genet Evol. 2007;7:52\u20139.","journal-title":"Infect Genet Evol"},{"key":"5363_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4269\/ajtmh.13-0129","volume":"89","author":"JA Flegg","year":"2013","unstructured":"Flegg JA, Metcalf CJE, Gharbi M, Venkatesan M, Shewchuk T, Hopkins Sibley C, Guerin PJ. Trends in antimalarial drug use in Africa. Am J Trop Med Hyg. 2013;89:857\u201365.","journal-title":"Am J Trop Med Hyg"},{"key":"5363_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-020-00712-4","volume":"9","author":"H Quan","year":"2020","unstructured":"Quan H, Igbasi U, Oyibo W, Omilabu S, Chen S-B, Shen H-M, Okolie C, Chen J-H, Zhou X-N. High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria. Infect Dis Poverty. 2020;9:1\u201311.","journal-title":"Infect Dis Poverty"},{"key":"5363_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.meegid.2015.08.039","volume":"36","author":"J Li","year":"2015","unstructured":"Li J, Chen J, Xie D, Eyi UM, Matesa RA, Obono MMO, Ehapo CS, Yang L, Yang H, Lin M. Molecular mutation profile of Pfcrt and Pfmdr1 in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea. Infect Genet Evol. 2015;36:552\u20136.","journal-title":"Infect Genet Evol"},{"key":"5363_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40360-015-0002-4","volume":"16","author":"AA Elmannan","year":"2015","unstructured":"Elmannan AA, Elmardi KA, Idris YA, Spector JM, Ali NA, Malik EM. Anti-malarial prescribing practices in Sudan eight years after introduction of artemisinin-based combination therapies and implications for development of drug resistance. BMC Pharmacol Toxicol. 2015;16:3.","journal-title":"BMC Pharmacol Toxicol"},{"key":"5363_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/trstmh\/trz059","volume":"113","author":"AMA Bakhiet","year":"2019","unstructured":"Bakhiet AMA, Abdelraheem MH, Kheir A, Omer S, Gismelseed L, Abdel-Muhsin AA, Naiem A, Al Hosni A, Al Dhuhli A, Al Rubkhi M, et al. Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan. Trans R Soc Trop Med Hyg. 2019;113:693\u2013700.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5363_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12936-019-2970-0","volume":"18","author":"NS Mohamed","year":"2019","unstructured":"Mohamed NS, Ali Albsheer MM, Abdelbagi H, Siddig EE, Mohamed MA, Ahmed AE, Omer RA, Muneer MS, Ahmed A, Osman HA, et al. Genetic polymorphism of the N-terminal region in circumsporozoite surface protein of Plasmodium falciparum field isolates from Sudan. Malar J. 2019;18:333.","journal-title":"Malar J"},{"key":"5363_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1086\/338566","volume":"185","author":"JG Kublin","year":"2002","unstructured":"Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME. Molecular markers for failure of sulfadoxine\u2013pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380\u20138.","journal-title":"J Infect Dis"},{"key":"5363_CR31","volume-title":"Evidence review group: intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine\u2013pyrimethamine (SP)","author":"WH Organization","year":"2012","unstructured":"Organization WH. Evidence review group: intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine\u2013pyrimethamine (SP). Geneva: WHO; 2012."},{"key":"5363_CR32","doi-asserted-by":"publisher","first-page":"e56183","DOI":"10.1371\/journal.pone.0056183","volume":"8","author":"WE Harrington","year":"2013","unstructured":"Harrington WE, Morrison R, Fried M, Duffy PE. Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring. PLoS ONE. 2013;8:e56183.","journal-title":"PLoS ONE"},{"key":"5363_CR33","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(98)07318-8","volume":"353","author":"C Shulman","year":"1999","unstructured":"Shulman C, Dorman E, Cutts F, Kawuondo K, Bulmer J, Peshu N, Marsh K. Intermittent sulphadoxine\u2013pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 1999;353:632\u20136.","journal-title":"Lancet"},{"key":"5363_CR34","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.1073\/pnas.0901415106","volume":"106","author":"W Harrington","year":"2009","unstructured":"Harrington W, Mutabingwa T, Muehlenbachs A, Sorensen B, Bolla M, Fried M, Duffy P. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci. 2009;106:9027\u201332.","journal-title":"Proc Natl Acad Sci"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-020-05363-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T05:54:09Z","timestamp":1669528449000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-05363-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5363"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-05363-0","relation":{},"ISSN":["1756-0500"],"issn-type":[{"type":"electronic","value":"1756-0500"}],"subject":[],"published":{"date-parts":[[2020,11,7]]},"assertion":[{"value":"5 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the National University Biomedical Research Ethics Committee, National University-Sudan. Oral and written informed consents were obtained from participants\u2019 or parents or guardians in case of children.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}